Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Neutrophil Elastase in the Pathogenesis of Chronic Obstructive Pulmonary Disease: A Review

Author(s): Pandit Bagus Tri Saputra, Dinda Dwi Purwati, Alyaa Ulaa Dhiya Ulhaq, Sherly Yolanda, Yovita Citra Eka Dewi Djatioetomo, Alfian Nur Rosyid* and Arief Bakhtiar

Volume 19, Issue 1, 2023

Published on: 10 November, 2022

Page: [29 - 35] Pages: 7

DOI: 10.2174/1573398X18666220929170117

Price: $65

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of mortality globally. It is associated with a low quality of life and socio-economic burden. Airway destruction in COPD pathogenesis is primarily due to the three mechanisms: protease-antiprotease imbalance, chronic airway inflammation, and oxidative stress, which is triggered by exposure to harmful particles, such as cigarette smoking. Neutrophil Elastase (NE), a serine protease stored in azurophilic granules of neutrophils, actively participates in airway remodeling and microbiocidal activity. It hydrolyzes elastin, collagen, and other vital Extracellular Matrix Proteins (EMP) in the respiratory tissue. In addition, neutrophil elastase activates other principal proteinases such as matrix metalloprotease (MMP)-2, MMP-9, Cathepsin B, Meprin α protease, and Calpain that amplify EMP degradation. Macrophage, the primary leukocyte, responsible for lung parenchymal inflammation in COPD, is also activated by NE. However, neutrophil elastase level is positively correlated with the degree of airway inflammation and disease severity. Neutrophil elastase activates reactive oxygengenerating systems such as Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase and myeloperoxidase and it also generates mitochondrial-derived-reactive oxygen species formation by inducing the secretion of Interleukin (IL)-1 and Tumour Necrosis Factor (TNF)- α. In addition, neutrophil elastase stimulates respiratory cell apoptosis by direct (e.g., activating the caspase-3 pathway) and indirect mechanisms (e.g., by secretion of Neutrophil Extracellular Traps). Surprisingly, neutrophil elastase may have small anti-inflammatory properties. In conclusion, neutrophil elastase is one of the main culprits responsible for COPD pathogenesis by mediating the activation of Triad COPD pathogenesis.

Keywords: COPD, neutrophil elastase, pathogenesis, pulmonary disease, chronic respiratory disease, extracellular matrix proteins (EMP).

« Previous Next »
Graphical Abstract

[1]
Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report 2019. Available from: https://goldcopd.org/
[2]
World Health Organization. Chronic obstructive pulmonary disease (COPD). 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD)
[3]
World Health Organization. The top 10 cause of death 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
[4]
Committee for the Third Edition of the COPD Guidelines of The Japanese Respiratory. Guidelines for the diagnosis and treatment of copd (chronic obstructive pulmonary disease). 3rd edition. 2010.
[5]
Fischer B, Pavlisko E, Voynow J. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6(1): 413-21.
[http://dx.doi.org/10.2147/COPD.S10770] [PMID: 21857781]
[6]
Yudhawati R, Prasetiyo YD. Imunopatogenesis of chronic obstructive pulmmonary disease. J Respir 2019; 4(1): 19.
[http://dx.doi.org/10.20473/jr.v4-I.1.2018.19-25]
[7]
Greulich T, Nell C, Hohmann D, et al. The prevalence of diagnosed α 1 -antitrypsin deficiency and its comorbidities: Results from a large population-based database. Eur Respir J 2017; 49(1): 1600154.
[http://dx.doi.org/10.1183/13993003.00154-2016]
[8]
Voynow JA, Shinbashi M. Neutrophil elastase and chronic lung disease. Biomolecules 2021; 11(8): 1065.
[http://dx.doi.org/10.3390/biom11081065] [PMID: 34439732]
[9]
Genschmer K, Russel D, Lal C, et al. Activated PMN exosomes: Pathogenic entities causing matrix destruction and disease in the lung KR. Physiol Behav 2020; 176(1): 100-6.
[10]
Goldklang M, Stockley R. Chronic obstructive pulmonary diseases: Journal of the COPD foundation pathophysiology of emphysema and implications. Chronic Obstr Pulm Dis 2016; 3(1): 454-8.
[http://dx.doi.org/10.15326/jcopdf.3.1.2015.0175]
[11]
Niemann CU, Åbrink M, Pejler G, et al. Neutrophil elastase depends on serglycin proteoglycan for localization in granules. Blood 2007; 109(10): 4478-86.
[http://dx.doi.org/10.1182/blood-2006-02-001719] [PMID: 17272511]
[12]
Tarhini M, Fessi HAB, Gerges H, Elaissari S. A potential new strategy for using elastase and its inhibitor as therapeutic agents. J Transl Sci 2019; 5(5): 1-8.
[13]
Tsai YF, Hwang TL. Neutrophil elastase inhibitors: A patent review and potential applications for inflammatory. Expert Opin Ther Patents 2015; 25(10): 1-14.
[14]
Pandey KC, De S, Mishra PK. Role of proteases in chronic obstructive pulmonary disease. Front Pharmacol 2017; 8(8): 512.
[http://dx.doi.org/10.3389/fphar.2017.00512] [PMID: 28848433]
[15]
Krotova K, Khodayari N, Oshins R, Aslanidi G, Brantly ML. Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway. Sci Rep 2020; 10(1): 15874.
[http://dx.doi.org/10.1038/s41598-020-72667-3] [PMID: 32981934]
[16]
Groutas WC, Dou D, Alliston KR. Neutrophil elastase inhibitors. Expert Opin Ther Pat 2011; 21(3): 339-54.
[http://dx.doi.org/10.1517/13543776.2011.551115]
[17]
Dicker AJ, Crichton ML, Pumphrey EG, et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141(1): 117-27.
[http://dx.doi.org/10.1016/j.jaci.2017.04.022] [PMID: 28506850]
[18]
Quintero PA, Knolle MD, Cala LF, Zhuang Y, Owen CA. Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 α to reduce acute lung inflammation and injury in mice. J Immunol 2010; 184(3): 1575-88.
[http://dx.doi.org/10.4049/jimmunol.0900290] [PMID: 20042585]
[19]
Kratzer E, Tian Y, Sarich N, et al. Oxidative stress contributes to lung injury and barrier dysfunction via microtubule destabilization. Am J Respir Cell Mol Biol 2012; 47(5): 688-97.
[http://dx.doi.org/10.1165/rcmb.2012-0161OC] [PMID: 22842495]
[20]
Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J Environ Res Public Health 2013; 10(9): 3886-907.
[http://dx.doi.org/10.3390/ijerph10093886] [PMID: 23985773]
[21]
Mizuno S, Yasuo M, Bogaard HJ, Kraskauskas D, Natarajan R, Voelkel NF. Inhibition of histone deacetylase causes emphysema. Am J Physiol Lung Cell Mol Physiol 2011; 300(3): L402-13.
[http://dx.doi.org/10.1152/ajplung.00207.2010] [PMID: 21224215]
[22]
Cavarra E, Lucattelli M, Gambelli F, et al. Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. Am J Physiol - Lung Cell Mol Physiol 2001; 281(2 25-2): 412-7.
[http://dx.doi.org/10.1152/ajplung.2001.281.2.L412]
[23]
Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002; 11(7): 965-80.
[http://dx.doi.org/10.1517/13543784.11.7.965] [PMID: 12084007]
[24]
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184(6): 662-71.
[http://dx.doi.org/10.1164/rccm.201104-0597OC] [PMID: 21680942]
[25]
Zheng S, Byrd A, Fischer B, Grover A, Ghio A, Voynow J. Regulation of MUC5AC expression by NAD(P)H: quinone oxidoreductase 1. Free Radic Biol Med 2007; 42(9): 1398-408.
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.01.040] [PMID: 17395013]
[26]
Karandashova S, Kummarapurugu AB, Zheng S, Chalfant CE, Voynow JA. Neutrophil elastase increases airway ceramide levels via upregulation of serine palmitoyltransferase. Am J Physiol Lung Cell Mol Physiol 2018; 314(1): L206-14.
[http://dx.doi.org/10.1152/ajplung.00322.2017] [PMID: 29025713]
[27]
Ferhani N, Letuve S, Kozhich A, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181(9): 917-27.
[http://dx.doi.org/10.1164/rccm.200903-0340OC] [PMID: 20133931]
[28]
Chirico V, Lacquaniti A, Leonardi S, et al. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection. Clin Microbiol Infect 2015; 21(4): 368.e1-9.
[http://dx.doi.org/10.1016/j.cmi.2014.11.004] [PMID: 25658530]
[29]
Thulborn SJ, Mistry V, Brightling CE, Moffitt KL, Ribeiro D, Bafadhel M. Neutrophil elastase as a biomarker for bacterial infection in COPD. Respir Res 2019; 20(1): 170.
[http://dx.doi.org/10.1186/s12931-019-1145-4] [PMID: 31362723]
[30]
Laurell CB, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15(2): 132-40.
[http://dx.doi.org/10.1080/00365516309051324]
[31]
Angelis N, Porpodis K, Zarogoulidis P, et al. Airway inflammation in chronic obstructive pulmonary disease. J Thorac Dis 2014; 6 (Suppl. 1): S167-72.
[PMID: 24672691]
[32]
Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017; 195(10): 1384-93.
[http://dx.doi.org/10.1164/rccm.201605-1027OC] [PMID: 27911604]
[33]
Clancy DM, Sullivan GP, Moran HBT, et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep 2018; 22(11): 2937-50.
[http://dx.doi.org/10.1016/j.celrep.2018.02.062] [PMID: 29539422]
[34]
Alfaidi M, Wilson H, Daigneault M, et al. Neutrophil elastase promotes interleukin-1β secretion from human coronary endothelium. J Biol Chem 2015; 290(40): 24067-78.
[http://dx.doi.org/10.1074/jbc.M115.659029] [PMID: 26269588]
[35]
Macleod T, Doble R, McGonagle D, et al. Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist. Sci Rep 2016; 6(1): 24880.
[http://dx.doi.org/10.1038/srep24880] [PMID: 27101808]
[36]
Rosyid AN, Maranatha D. Methacholin provocation test in COPD and healthy smokers. Curr Respir Med Rev 2018; 13(3): 168-74.
[http://dx.doi.org/10.2174/1573398X14666180213092735]
[37]
Koga H, Miyahara N, Fuchimoto Y, et al. Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses. Respir Res 2013; 14(1): 8.
[http://dx.doi.org/10.1186/1465-9921-14-8] [PMID: 23347423]
[38]
Kirkham PA, Barnes PJ. Oxidative Stress in COPD. Chest 2013; 144(1): 266-73.
[http://dx.doi.org/10.1378/chest.12-2664] [PMID: 23880677]
[39]
Branzk N, Lubojemska A, Hardison SE, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 2014; 15(11): 1017-25.
[http://dx.doi.org/10.1038/ni.2987] [PMID: 25217981]
[40]
Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986; 83(18): 6692-6.
[http://dx.doi.org/10.1073/pnas.83.18.6692] [PMID: 3462719]
[41]
Wencker M, Fuhrmann B, Konietzko N, Banik N. Longitudinal follow-up of patients with α(1)-protease inhibitor deficiency before and during therapy with IV α(1)-protease inhibitor. Chest 2001; 119(3): 737-44.
[http://dx.doi.org/10.1378/chest.119.3.737] [PMID: 11243951]
[42]
Alcazar AMA, Kaschwich M, Ertsey R, et al. Elafin treatment rescues EGFT-KLF4 signaling and lung cell survival in ventilated newborn mice. Am J Respir Cell Mol Biol 2018; 59(5): 623-34.
[http://dx.doi.org/10.1165/rcmb.2017-0332OC] [PMID: 29894205]
[43]
Bachovchin WW. Nitrogen-15 NMR spectroscopy of hydrogen-bonding interactions in the active site of serine proteases: Evidence for a moving histidine mechanism. Biochemistry 1986; 25(23): 7751-9.
[http://dx.doi.org/10.1021/bi00371a070] [PMID: 3542033]
[44]
Stein RL, Strimpler AM, Hori H, Powers JC. Catalysis by human leukocyte elastase: mechanistic insights into specificity requirements. Biochemistry 1987; 26(5): 1301-5.
[http://dx.doi.org/10.1021/bi00379a015] [PMID: 3646070]
[45]
Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial. Lancet 2015; 386(9991): 360-8.
[http://dx.doi.org/10.1016/S0140-6736(15)60860-1] [PMID: 26026936]
[46]
Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced α 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α 1-antitrypsin deficiency. J Clin Invest 1989; 84(4): 1349-54.
[http://dx.doi.org/10.1172/JCI114305] [PMID: 2794066]
[47]
Vogelmeier C, Aquino TO, O’Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 2012; 9(2): 111-20.
[http://dx.doi.org/10.3109/15412555.2011.641803] [PMID: 22458939]
[48]
Kuna P, Jenkins M, O’Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med 2012; 106(4): 531-9.
[http://dx.doi.org/10.1016/j.rmed.2011.10.020] [PMID: 22197578]
[49]
Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996; 9(7): 1482-6.
[http://dx.doi.org/10.1183/09031936.96.09071482] [PMID: 8836663]
[50]
Wang ZQ, Chen LQ, Yuan Y, et al. Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21(12): 3720-30.
[http://dx.doi.org/10.3748/wjg.v21.i12.3720] [PMID: 25834341]
[51]
Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013; 107(4): 524-33.
[http://dx.doi.org/10.1016/j.rmed.2012.12.009] [PMID: 23433769]

Rights & Permissions Print Cite
Article Metrics
26
2
© 2024 Bentham Science Publishers | Privacy Policy